Pacira Pharmaceuticals Given Consensus Recommendation of “Buy” by Analysts (NASDAQ:PCRX)
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) have been given a consensus recommendation of “Buy” by the ten ratings firms that are covering the stock, AR Network reports. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $104.68.
Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 104.41 on Thursday. Pacira Pharmaceuticals has a one year low of $35.98 and a one year high of $106.42. The stock’s 50-day moving average is $92.65 and its 200-day moving average is $78.84. The company’s market cap is $3.747 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.04 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.21) by $0.25. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $42.20 million. The company’s quarterly revenue was up 175.2% on a year-over-year basis. On average, analysts predict that Pacira Pharmaceuticals will post $0.23 earnings per share for the current fiscal year.
In other Pacira Pharmaceuticals news, Director Andreas Wicki sold 150,000 shares of the stock on the open market in a transaction dated Monday, August 11th. The shares were sold at an average price of $101.25, for a total transaction of $15,187,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
A number of research firms have recently commented on PCRX. Analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals from $98.00 to $110.00 in a research note on Friday, August 1st. Separately, analysts at Canaccord Genuity raised their price target on shares of Pacira Pharmaceuticals to $114.00 in a research note on Friday, August 1st. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 1st. They now have a $109.00 price target on the stock, up previously from $86.00.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.